Revive TherapeuticsRVVTF 
12.50%24h
Revive Therapeutics (RVVTF) Stock Overview
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers cannabinoid pharmaceutical portfolio that focuses on rare inflammatory diseases. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and COVID-19; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. The company is based in Toronto, Canada.
RVVTF Stock Information
Revive Therapeutics (RVVTF) Price Chart
Revive Therapeutics Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.009 | N/A |
| Market Cap | $3.05M | N/A |
| Shares Outstanding | 339.37M | 6.13% |
| Employees | 0 | N/A |
| Shareholder Equity | 10.65M | -15.47% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.45 | N/A |
| P/B Ratio | 0.29 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.4358 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$4.64M | N/A |
| EPS | -0.02 | N/A |
| Earnings Yield | -2.22 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $10.47M | N/A |
| Total Debt | $161.37K | N/A |
| Cash on Hand | $1.53M | N/A |
| Debt to Equity | 0.2482 | -4.59% |
| Cash to Debt | $9.50 | -20.47% |
| Current Ratio | 0.6846 | -31.50% |
